Author:
Miladi Imen,Vivier Magali,Dauplat Marie-Mélanie,Chatard Morgane,Besse Sophie,Vidal Aurélien,Chassain Karine,Jean Betty,Forestier Christiane,Chezal Jean-Michel,Rédini Francoise,Degoul Francoise,Miot-Noirault Elisabeth
Funder
Financial support: Fondation pour la Recherche Médicale (FRM)
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference34 articles.
1. Angelini A, Guerra G, Mavrogenis AF, Pala E, Picci P, Ruggieri P (2012) Clinical outcome of central conventional chondrosarcoma. J Surg Oncol 106:929–937
2. van Maldegem AM, Gelderblom H, Palmerini E, Dijkstra SD, Gambarotti M, Ruggieri P, Nout RA, van de Sande MA, Ferrari C, Ferrari S, Bovée JV, Picci P (2014) Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer 120(20):3159–3164
3. Heymann D, Redini F (2013) Targeted therapies for bone sarcomas. Bonekey Rep 2:378
4. Dai X, Ma W, He X, Jha RK (2011) Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. Med Sci Monit 17(8):RA177–RA190
5. Wang P, Guan PP, Wang T, Yu X, Guo JJ, Konstantopoulos K, Wang ZY (2014) Interleukin-1β and cyclic AMP mediate the invasion of sheared chondrosarcoma cells via a matrix metalloproteinase-1-dependent mechanism. Biochim Biophys Acta 1843(5):923–933
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献